Lingkang pharmaceutical acquired Hainan cancer hospital assets with a revenue of 0.1 billion yuan

[China Pharmaceutical network enterprise news] recently, Lingkang pharmaceutical, a listed company, announced a plan to acquire part of the equity of Chengmei International Medical Center (hereinafter referred to as "Chengmei international") of Hainan Cancer Hospital, the main operating body of Boao super hospital in Hainan Province According to the plan, Lingkang pharmaceutical will purchase 25% equity of Chengmei international held by Hainan Cancer Hospital Co., Ltd (hereinafter referred to as "Hainan cancer hospital") with 100 million yuan in cash The reporter of Beijing News noted that after the acquisition, Chengmei international, with a total valuation of 400 million yuan, had zero operating revenue in 2017 and January March 2018 Chengmei international holds the medical institution license of Boao super hospital, but Boao super hospital is still in its infancy In addition, Chengmei International's subsidiaries, rehabilitation and pension center, and lishkangsheng, a sun company, have incurred an operating loss of 14.0238 million yuan over the years It is worth noting that Jiang Huicheng, a rich man in Hainan, became the ultimate controller of Chengmei international with a relatively low shareholding ratio On August 25, Lingkang pharmaceutical replied to the reporter of Beijing news that through the layers of retrospection of the equity structure of Chengdu Meiji international and the principle that substance is more important than form, Jiang would eventually be recognized as the controller of Chengdu Meiji international Prior to the acquisition, a series of shareholders with state-owned background in Hainan entered into Chengdu Meiji international in February this year, and the equity delivery has not been completed so far, while the valuation of Chengdu Meiji international is 60% higher than that of the state-owned capital in one month In May this year, Lingkang pharmaceutical and Hainan Cancer Hospital signed a framework agreement on the acquisition of Chengmei international and reached a formal agreement in August On August 22, Lingkang pharmaceutical announced that the company signed an equity transfer agreement with Hainan Cancer Hospital, which will purchase 25% of the equity of Chengmei international held by Hainan cancer hospital with 100 million yuan in cash On February 28, 2013, the State Council officially approved the establishment of Boao Lecheng International Medical Tourism pilot area in Hainan, and gave a number of support policies Boao super hospital is located here At the end of March this year, Boao super hospital officially started operation As of June 30, there were 91 employees, still in the initial stage Boao super hospital holds a medical institution license, which is valid from the end of 2017 to the end of 2032 In 2017 and January March 2018, the newly started Chengmei International's operating revenue was 0, and its net profit was - 7.1904 million yuan and - 3.8555 million yuan respectively In addition, the subsidiaries of Chengmei international, rehabilitation and pension center, and lishkangsheng, the sun company, also suffered from operating losses over the years, totaling 14.0238 million yuan It is worth noting that in Boao Lecheng International Medical Tourism Pioneer Area, there are also Yuanhe 301 medical center, Ciming AoYa chronic disease rehabilitation hospital, maritime Silk Road stem cell medical center and other hospitals Lingkang pharmaceutical said in the announcement that if Boao super hospital can not maintain its advantages, it may gradually lose its dominant position in the constantly competitive market environment Lingkang pharmaceutical said that Boao super hospital will not have an impact on the company's operating performance in the short term, "the subsequent profitability depends on the business development." Under such performance risk, the acquisition does not involve any performance commitment On August 25, Lingkang pharmaceutical replied to the Beijing news that the acquisition did not involve the performance commitments made by Chengmei international or Hainan cancer hospital "In the future planning of the company, Chengmei international is a window and platform for docking international advanced medical technology and domestic unlisted drugs and medical devices." In February this year, the subject company introduced state-owned shareholders, and purchased 25% of the shares of Chengmei international at a valuation premium of 60% and 100 million yuan, which corresponds to the total valuation of 400 million yuan of Chengmei international A reporter from Beijing News found that the benchmark date for the valuation is March 31, 2018 In February 2018, Chengmei international also made a change in equity, with a corresponding total valuation of 249 million yuan According to the audit report of Hainan cancer hospital Chengmei International Medical Center Co., Ltd disclosed by Lingkang pharmaceutical, Chengmei international was established by Hainan cancer hospital at the end of 2015, with the latter holding 80.32% of the shares and the other shareholder Hainan information industry venture capital fund (limited partnership) holding 19.68% Lingkang Pharmaceutical Co., Ltd told Beijing News on August 25 that in February 2018, in order to further develop Boao super hospital, Chengmei international signed a capital increase agreement with Hainan information industry venture capital fund (limited partnership) The industrial fund increased its capital by 49 million yuan per share, accounting for 19.68% of the paid in capital after the capital increase In February, the company increased its capital by 49 million yuan to obtain the result of holding 19.68% of the shares At that time, the corresponding total valuation of Chengmei international was 249 million yuan By contrast, the total valuation of the company's 400 million yuan at the end of March generated a 60% premium According to Tianyan survey, the major shareholders of Hainan information industry venture capital fund are mainly state-owned enterprises such as Hainan Development Holding Co., Ltd., Haikou national high tech Zone Development Holding Co., Ltd and Datang Telecom Technology Industry Holding Co., Ltd Lingkang pharmaceutical told reporters that as of August 22, the industrial and commercial change procedures of Hainan information industry venture capital fund for capital increase of Chengmei international had not been completed In the acquisition announcement, the industrial and commercial registration information (legally) was disclosed, indicating that Hainan cancer hospital holds 100% of Chengmei international Why did Lingkang pharmaceutical choose to purchase the assets of a tumor hospital? In May 2015, Lingkang pharmaceutical, which was listed in a share, mainly produced and sold anti infective, parenteral nutrition and digestive system drugs As early as in the 2015 annual report, Lingkang pharmaceutical disclosed that "the company's R & D projects cover the fields of anti-tumor drugs, cardiovascular and cerebrovascular drugs, digestive system drugs and other major diseases" On August 24, a reporter from Beijing News told Lingkang Pharmaceutical Co., Ltd about the company's development of anti-tumor drugs Lingkang pharmaceutical replied that "in the field of anti-tumor targeted drugs, the company actively contacts and cooperates closely with domestic and foreign innovative drug R & D institutions and R & D teams to preliminarily determine the focus and direction of R & D work The R & D of anti-tumor drugs of the company is still in the stage of screening and project approval." After the acquisition of some shares of Chengmei international, whether it will be combined with the anti-tumor drug research and development project of Lingkang pharmaceutical, Lingkang pharmaceutical replied to the reporter of Beijing news that Boao super hospital will provide talent and technical assistance for the anti-tumor drug research and development of the company However, considering that the research and development of tumor drugs is a long-term systematic work, and the research and development work also has great uncertainty, it is unable to assess its specific impact at present The reporter of Beijing News noted that the proportion of R & D investment of Lingkang pharmaceutical industry decreased year by year The R & D investment in 2015, 2016 and 2017 was 38.57 million yuan, 29.34 million yuan and 47.4 million yuan respectively, accounting for 7.01%, 6.13% and 4.72% of the operating revenue At the same time, the ultimate controller of Chengmei international, which controls Hainan Cancer Hospital, is Jiang Huicheng The parent company of Chengmei international is Hainan cancer hospital According to Tianyan survey data, the major shareholders of Hainan cancer hospital are Hainan Cancer Hospital, Haikou Financial Investment Management Co., Ltd and Hainan investment holding group Co., Ltd controlled by Jiang Huicheng (hereinafter referred to as "first investment group"), with the shareholding ratio of 58.33%, 25% and 16.67% respectively After equity penetration, Hainan Cancer Hospital, Haikou municipal government state owned assets supervision and Administration Commission and Jiang Huicheng respectively held 53.08%, 23.05% and 16% of the equity of Hainan cancer hospital According to Lingkang pharmaceutical's announcement, Jiang Huicheng was recognized as the final controller of Hainan cancer hospital and Chengmei international On August 25, Lingkang pharmaceutical said to the reporter of Beijing news that it was "finally determined that Jiang would become the controller of Chengdu Meiji international medical center by tracing the ownership structure of Chengdu Meiji international medical center layer by layer and the principle that substance is more important than form." In the news of Hainan Cancer Hospital, in June this year, Jiang Huicheng also attended the relevant signing ceremony as the director general of Hainan cancer hospital As early as 2010, Jiang Huicheng began to lead the development of Hainan cancer hospital In 2015, a report in Hainan Daily said, "in 2010, after learning that Hainan provincial Party committee and provincial government decided to take the lead in adopting the mixed ownership reform in China, with social capital investment holding the shares and building a high-level specialized Tumor Hospital, the investment (Group) seeking transformation seized the opportunity." Jiang Huicheng put the group's efforts into the construction of Hainan tumor hospital Setting " Jiang Huicheng's capital territory has a deep intersection with Hainan cancer hospital According to the data of Hainan Cancer Hospital, Hainan cancer hospital and Hainan cancer prevention and control center is a non-profit three-level Cancer Hospital under the leadership of Hainan health and Family Planning Commission, which undertakes the cancer prevention and control work of the whole province It also said that the hospital "cooperates with the Chengmei charity foundation to provide assistance for poor patients who come to the hospital for medical treatment." According to the 2017 annual work report of Chengmei charity foundation, the foundation was established in 2010, with the original fund amount of 50 million yuan The investor is Yitou group and Hainan cancer hospital The business competent unit is the Department of civil affairs of Hainan Province, and the legal representative and director general are Jiang Huicheng From Hainan cancer hospital to Chengmei international, will Jiang Huicheng or his representative group become the main decision maker of Chengmei international? Lingkang pharmaceutical replied to reporters on August 25 that "the ultimate controller of Chengmei International Medical Center is Jiang Huicheng In the future, it will not be ruled out that it will reduce its shareholding ratio by transferring shares to introduce new shareholders and other measures, resulting in the decentralization of its controlling right." - the character Jiang Huicheng returned to A-share market in 2002 The 33 year old Hainan investment and investment promotion Co., Ltd controlled by Jiang Huicheng was listed The stock is called investment for short At that time, the investment was jointly initiated and established by the first investment group controlled by Jiang Huicheng, Hainan Chuanjing Cooperative Trading Company, Hainan Everbright Guoxin Real Estate Development Co., Ltd At that time, Jiang Huicheng also served as a member of the CPPCC Hainan Provincial Committee, member of the Standing Committee of the CPPCC Haikou Municipal Committee, vice chairman of Hainan Youth Federation, vice chairman of Hainan General Chamber of Commerce, President of Hainan International Chamber of Commerce, President of Haikou General Chamber of Commerce and vice chairman of Hainan Entrepreneurs Association Since September 2004, the investment shares held by Yitou group have been frozen by the court In October of that year, several properties invested were seized In May 2005, the investment changed its name to st investment In 2006, the first investment group was unable to repay the investment in cash, shares and other ways, so it had to take out assets as compensation In 2007, the investment shares held by Yitou group were auctioned, and Jiang Huicheng lost his identity as the actual controller of investment A reporter from Beijing News found that since 2018, Jiang Huicheng has appeared in A-share for many times In the appendix of the letter of intent of the listed company Fuda alloy in April this year, Jiang Huicheng appeared in the list of natural person shareholders of Fuda alloy through equity penetration In May this year, Fuda alloy was successfully listed Jiang Huicheng was also on the list of shareholders of bertley listed in April this year In the plan to acquire 100% equity of lanchuang intelligent issued by boss in April this year, the name of Jiang Huicheng also appeared in the penetration verification of the transaction party The reporter found that Jiang Huicheng mainly holds the equity of Shoutai investment group through the investment group, which is the shareholder of Shenzhen chuangdong Investment Co., Ltd According to Tianyan data, Shenzhen chuangdongzao